The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine-Reference-Cited by-同舟云学术

The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine

Published:2020-09 Issue: Volume:403 Page:115163
ISSN:0041-008X
Container-title:Toxicology and Applied Pharmacology
language:en
Short-container-title:Toxicology and Applied Pharmacology

Author:

Jolly Carol E.,Douglas Oisin,Kamalian Laleh,Jenkins Rosalind E.,Beckett Alison J.,Penman Sophie L.,Williams Dominic P.,Monshouwer Mario,Simic Damir,Snoeys Jan,Park B. Kevin,Chadwick Amy E.

Funder

Innovative Medicines Initiative

Janssen Pharmaceutica

Medical Research Council

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference30 articles.

1. Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry;FDA,2015

2. Etiology and therapeutic approach to elevated lactate levels;Andersen;Mayo Clin. Proc.,2013

3. Identification of the additional mitochondrial liabilities of 2-Hydroxyflutamide when compared with its parent compound, Flutamide in HepG2 cells;Ball;Toxicol. Sci.,2016